Profile data is unavailable for this security.
About the company
Precision BioSciences, Inc. is a clinical-stage gene editing company dedicated to improving life (DTIL) with its proprietary ARCUS genome editing platform. Using ARCUS, the Company’s pipeline is comprised of in vivo gene editing candidates designed to deliver cures for a range of genetic and infectious diseases. The ARCUS platform is used to develop in vivo gene editing therapies for gene edits, including gene insertion, elimination, and excision. The Company's in vivo gene editing pipeline programs include PBGENE-HBV, PBGENE-3243, PBGENE-DMD, PBGENE-LIVER, PBGENE-CNS, PBGENE-NVS and iECURE-OTC. PBGENE-HBV is its lead in vivo gene editing program designed to eliminate cccDNA, the key source of replicating hepatitis B virus (HBV) and inactivating integrated HBV DNA in hepatocytes. Its PBGENE-3243 program is a first of its kind potential treatment for m.3243 associated mitochondrial disease. The Company's iECURE-OTC program is developed in partnership with iECURE, Inc.
- Revenue in USD (TTM)698.00k
- Net income in USD-83.60m
- Incorporated2006
- Employees67.00
- LocationPrecision BioSciences Inc302 E Pettigrew St Ste A100DURHAM 27701-2393United StatesUSA
- Phone+1 (302) 658-7581
- Fax+1 (302) 655-5049
- Websitehttps://precisionbiosciences.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ibio Inc | 300.00k | -24.74m | 92.92m | 20.00 | -- | 1.43 | -- | 309.74 | -1.26 | -1.26 | 0.0112 | 1.88 | 0.007 | -- | -- | 15,000.00 | -57.47 | -30.90 | -65.55 | -37.76 | -- | -- | -8,245.67 | -2,374.12 | -- | -- | 0.00 | -- | 77.78 | -24.57 | -19.00 | -- | -57.50 | -- |
| Citius Oncology Inc | 3.94m | -23.64m | 93.57m | -- | -- | 1.54 | -- | 23.72 | -0.3102 | -0.3102 | 0.0511 | 0.6889 | 0.0394 | 0.0426 | -- | -- | -23.58 | -- | -42.08 | -- | 79.99 | -- | -599.28 | -- | 0.3245 | -112.34 | 0.0611 | -- | -- | -- | -17.08 | -- | -- | -- |
| Biomea Fusion Inc | 0.00 | -95.71m | 94.04m | 42.00 | -- | 5.07 | -- | -- | -2.39 | -2.39 | 0.00 | 0.2625 | 0.00 | -- | -- | 0.00 | -115.59 | -62.24 | -156.30 | -68.84 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -18.06 | -- | -- | -- |
| aTyr Pharma Inc | 190.00k | -75.12m | 94.06m | 56.00 | -- | 1.17 | -- | 495.04 | -0.8345 | -0.8345 | 0.0021 | 0.8188 | 0.0019 | -- | 0.1323 | 3,392.86 | -75.78 | -47.98 | -88.99 | -54.91 | -- | -- | -39,540.53 | -978.90 | -- | -- | 0.0127 | -- | -33.43 | -11.05 | -27.06 | -- | -3.83 | -- |
| TuHURA Biosciences Inc | 0.00 | -43.77m | 94.12m | 19.00 | -- | 4.82 | -- | -- | -1.60 | -1.60 | 0.00 | 0.3273 | 0.00 | -- | -- | 0.00 | -286.97 | -- | -456.76 | -- | -- | -- | -- | -- | -- | -9.01 | 0.0286 | -- | -- | -- | -- | -- | -- | -- |
| Anixa Biosciences Inc | 0.00 | -10.93m | 94.46m | 4.00 | -- | 6.16 | -- | -- | -0.3369 | -0.3369 | 0.00 | 0.4593 | 0.00 | -- | -- | 0.00 | -58.55 | -47.85 | -62.09 | -49.81 | -- | -- | -- | -8,381.30 | -- | -- | 0.00 | -- | -- | -- | 12.96 | -- | -- | -- |
| Dogwood Therapeutics Inc | 0.00 | -39.98m | 97.56m | 12.00 | -- | -- | -- | -- | -24.92 | -24.92 | 0.00 | 33.75 | 0.00 | -- | -- | 0.00 | -81.05 | -52.48 | -84.58 | -55.93 | -- | -- | -- | -- | -- | -178.51 | 0.00 | -- | -- | -- | -142.90 | -- | -- | -- |
| Precision BioSciences Inc | 698.00k | -83.60m | 99.60m | 67.00 | -- | 3.16 | -- | 142.70 | -8.40 | -8.40 | 0.0695 | 1.38 | 0.0057 | -- | 0.9001 | 6,462.96 | -67.76 | -26.22 | -76.07 | -33.68 | -- | -- | -11,977.36 | -87.80 | -- | -190.84 | 0.5736 | -- | 40.98 | 25.30 | 116.85 | -- | -59.31 | -- |
| Turn Therapeutics Inc | -100.00bn | -100.00bn | 101.00m | -- | -- | 190.70 | -- | -- | -- | -- | -- | 0.018 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 22.85 | -- | -- | -- |
| Gain Therapeutics Inc | 0.00 | -19.39m | 101.16m | 23.00 | -- | 16.01 | -- | -- | -0.6364 | -0.6364 | 0.00 | 0.1643 | 0.00 | -- | -- | 0.00 | -153.07 | -79.58 | -234.03 | -95.32 | -- | -- | -- | -19,975.78 | -- | -33.79 | 0.067 | -- | -100.00 | -- | 8.34 | -- | 10.39 | -- |
| Korro Bio Inc | 7.37m | -88.42m | 101.24m | 87.00 | -- | 1.02 | -- | 13.73 | -9.42 | -9.42 | 0.7855 | 10.54 | 0.0364 | -- | 1.36 | 70,875.00 | -43.65 | -- | -46.92 | -- | -- | -- | -1,199.53 | -- | -- | -- | 0.00 | -- | -- | -- | -2.97 | -- | -- | -- |
| Goldenwell Biotech Inc | 62.50k | -75.13k | 103.95m | -- | -- | -- | -- | 1,663.20 | -0.0007 | -0.0007 | 0.0006 | -0.001 | 0.3126 | 0.00 | -- | -- | -37.58 | -95.49 | -41.82 | -110.12 | 100.00 | 52.18 | -120.21 | -2,064.27 | 1.16 | -4.11 | 124.14 | -- | -92.39 | -13.55 | -12.05 | -- | -- | -- |
| Aardvark Therapeutics Inc | 0.00 | -48.77m | 106.69m | 33.00 | -- | 0.8707 | -- | -- | -2.53 | -2.53 | 0.00 | 5.63 | 0.00 | -- | -- | -- | -44.96 | -- | -47.90 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -185.63 | -- | -- | -- |
| Cassava Sciences Inc | 0.00 | -106.03m | 107.24m | 30.00 | -- | 1.31 | -- | -- | -2.20 | -2.20 | 0.00 | 1.69 | 0.00 | -- | -- | 0.00 | -59.99 | -28.22 | -85.37 | -29.72 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 74.96 | -- | 41.75 | -- |
| Kazia Therapeutics Ltd (ADR) | 80.18k | -14.56m | 107.43m | 12.00 | -- | -- | -- | 1,339.93 | -12.21 | -12.21 | 0.0558 | -3.61 | 0.0083 | -- | 0.0571 | -- | -149.76 | -64.49 | -- | -99.77 | -- | -- | -18,159.65 | -573.31 | -- | -- | -- | -- | -95.09 | 11.58 | 22.69 | -- | -- | -- |
| Equillium Inc | 4.39m | -24.42m | 107.78m | 35.00 | -- | 3.47 | -- | 24.54 | -0.632 | -0.632 | 0.1021 | 0.5099 | 0.1274 | -- | 1.71 | 125,485.70 | -70.81 | -44.86 | -89.09 | -58.85 | -- | -- | -555.94 | -164.30 | -- | -- | 0.00 | -- | 13.89 | -- | 39.51 | -- | 2.81 | -- |
Data as of Mar 03 2026. Currency figures normalised to Precision BioSciences Inc's reporting currency: US Dollar USD
74.93%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Empery Asset Management LPas of 31 Dec 2025 | 2.19m | 18.62% |
| abrdn, Inc.as of 31 Dec 2025 | 2.14m | 8.88% |
| Octagon Capital Advisors LPas of 31 Dec 2025 | 1.92m | 16.27% |
| Bleichroeder LPas of 31 Dec 2025 | 1.66m | 6.91% |
| Boothbay Fund Management LLCas of 31 Dec 2025 | 1.07m | 4.43% |
| Lynx1 Capital Management LPas of 31 Dec 2025 | 993.91k | 8.43% |
| Alyeska Investment Group LPas of 31 Dec 2025 | 798.00k | 3.32% |
| Driehaus Capital Management LLCas of 31 Dec 2025 | 787.70k | 3.27% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 760.12k | 3.16% |
| Sphera Funds Management Ltd.as of 31 Dec 2025 | 396.12k | 1.65% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
